Fibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy Group

Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that it will present at the 2014 Patient Care Conference of the Dystrophic Epidermolysis Bullosa Research Association of America (DebRA) as part of the company’s commitment to engage and support advocacy groups for patients with rare diseases. Held every other year, this educational forum brings together patients and their families to connect with one another and hear about new research for epidermolysis bullosa (EB). John Maslowski, vice president of scientific affairs at Fibrocell, will discuss the company’s commitment to genetically-modified, autologous human fibroblasts for the treatment of recessive dystrophic epidermolysis bullosa, RDEB, the most severe form of dystrophic EB. This year’s DebRA Patient Care Conference is scheduled for July 30 – August 2 in Nashville, Tenn.

“We are honored to support this important conference for RDEB patients and their families. These patients’ fibroblasts do not produce functional collagen VII, the essential protein that forms anchoring fibrils responsible for holding together layers of skin. In collaboration with Intrexon Corporation (NYSE: XON), we are developing genetically-modified autologous fibroblasts—encoded with the gene for functional collagen VII—that have the potential to treat the underlying genetic cause of this devastating disease and relieve the pain and suffering of patients,” said David Pernock, chairman and chief executive officer of Fibrocell. “Being an active participant in this forum further solidifies our commitment to developing a therapeutic solution for RDEB and other rare diseases.”

Fibrocell is working with leading medical centers—whose research focuses on all forms of epidermolysis bullosa—to advance development of its lead therapeutic candidate for RDEB. The genetically-modified fibroblasts combine Fibrocell’s autologous fibroblast technology with Intrexon Corporation’s UltraVector® synthetic biology platform to target the fundamental source of this genetic disease that causes severe blistering and areas of missing skin. In June 2014, Fibrocell announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to its genetically-modified autologous human fibroblasts to treat dystrophic epidermolysis bullosa, a broad category of rare and severe genetic skin diseases that includes RDEB.

“I am very excited that Fibrocell, our 2013 Partners in Progress Award recipient, is presenting at this year’s Patient Care Conference” said Brett Kopelan, executive director of DebRA of America. “I know the EB community is excited to learn more about the work they are engaging in and how it has the potential to help the RDEB community”.

About Dystrophic Epidermolysis Bullosa Research Association of America (DebRA)

The Dystrophic Epidermolysis Bullosa Research Association of America (DebRA) founded in 1980, is headquartered in New York City, and is the only national nonprofit that supports the research for treatments and a cure, while providing services and programs to those who suffer from Epidermolysis Bullosa (EB). Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic connective tissue disorder in which people do not produce a vital protein which allows their skin to adhere to itself, rendering the skin so fragile that even the slightest friction can cause severe blistering and skin tears. The list of secondary complications can be long and requires multiple interventions from a range of medical specialists given that internal organs and bodily systems can also be seriously affected. For additional information, please visit www.debra.org.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (NYSE MKT: FCSC) is an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Based on its proprietary autologous fibroblast technology, Fibrocell is pursuing breakthrough medical applications of azficel-T for restrictive burn scarring and vocal cord scarring. The company’s collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology, includes using genetically-modified fibroblasts for treating rare and serious skin and connective tissue diseases for which there are no currently approved products. For additional information, please visit www.fibrocellscience.com.

Forward-Looking Statements

This press release contains, and our officers and representatives may from time to time make, statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include, among others, statements we make regarding our ability to develop breakthrough therapies for the treatment of skin and connective tissues diseases, and to expand our proprietary Personalized Biologics platform. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of Fibrocell Science’s control. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) uncertainties relating to the initiation and completion of clinical trials; (ii) whether clinical trial results will validate and support the safety and efficacy of azficel-T; and (iii) our ability to establish additional strategic partnerships, as well as those set forth under the caption “Item 1A. Risk Factors” in Fibrocell Science’s most recent Form 10-K filing, as updated in “Item 1A. Risk Factors” in Fibrocell Science’s most recent Form 10-Q filing. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. In addition, Fibrocell Science operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, you should not place any reliance on forward-looking statements as a prediction of actual results. Fibrocell Science disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. You are also urged to carefully review and consider the various disclosures in Fibrocell Science’s most recent annual report on Form 10-K, our most recent Form 10-Q as well as other public filings with the SEC since the filing of Fibrocell Science’s most recent annual report.